NCI/X
Dec 21, 2024, 14:00
NCI Division of Cancer Prevention – DHT Derived Biomarkers and COAs for Remote Monitoring and Endpoint Development
NCI Division of Cancer Prevention shared on LinkedIn:
“New Funding Opportunity! This NOFO is to support rigorous development and validation of Digital Health Technology (DHT) derived biomarkers or clinical outcome assessments (COAs) for remote monitoring to fill a defined unmet clinical endpoint for interventional clinical trials. This includes development and validation of digital biomarkers to monitor cancer treatment related symptoms, sequelae, and/or outcomes (e.g., pain, cognitive impairment, adverse events, late effects toxicity). PAR-25-170
Expires: June 23, 2026.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 22:40
Dec 21, 2024, 22:37
Dec 21, 2024, 22:26
Dec 21, 2024, 19:39
Dec 21, 2024, 19:21
Dec 21, 2024, 19:19